Lisa Susan Wieland

Lisa Susan Wieland

Auto-generated profile, based on publicly available information

Lisa Susan Wieland

Department of Biochemistry and Cellular & Molecular Biology, Division of Integrative Physiology, Georgetown University School of Medicine, Washington, DC, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LWL. Susan Wieland
L. Susan Wieland
NSNicole Skoetz
Nicole Skoetz
KPKaren Pilkington
Karen Pilkington
RVRamaprabhu Vempati
Ramaprabhu Vempati
CDChristopher R D'ADamo
Christopher R D'ADamo
BBBrian M Berman
Brian M Berman

10 December 2019 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
MPMisty Pratt
Misty Pratt
ASAdrienne Stevens
Adrienne Stevens
MTMicere Thuku
Micere Thuku
CBClaire Butler
Claire Butler
BSBecky Skidmore
Becky Skidmore
BHBrian Hutton
Brian Hutton
Background: There has been increased interest in the role of cannabis for treating medical conditions. The availability of different cannabis-based products can make the side effects of exposure unpredictable. We sought to conduct a scoping review of systematic reviews assessing benefits and harms of cannabis-based medicines for any condition.Methods: A protocol was followed throughout the conduct of this scoping review. A protocol-guided scoping review conduct. Searches of bibliographic databases (e.g., MEDLINE®, Embase, PsycINFO, the Cochrane Library) and gray literature were performed. Two people selected and charted data from systematic reviews. Categorizations emerged during data synthesis. The reporting of results from systematic reviews was performed at a high level appropriate for a scoping review.Results: After screening 1975 citations, 72 systematic reviews were included. The reviews covered many conditions, the most common being pain management. Several reviews focused on management of pain as a symptom of conditions such as multiple sclerosis (MS), injury, and cancer. After pain, the most common symptoms treated were spasticity in MS, movement disturbances, nausea/vomiting, and mental health symptoms. An assessment of review findings lends to the understanding that, although in a small number of reviews results showed a benefit for reducing pain, the analysis approach and reporting in other reviews was sub-optimal, making it difficult to know how consistent findings are when considering pain in general. Adverse effects were reported in most reviews comparing cannabis with placebo (49/59, 83%) and in 20/24 (83%) of the reviews comparing cannabis to active drugs. Minor adverse effects (e.g., drowsiness, dizziness) were common and reported in over half of the reviews. Serious harms were not as common, but were reported in 21/59 (36%) reviews that reported on adverse effects. Overall, safety data was generally reported study-by-study, with few reviews synthesizing data. Only one review was rated as high quality, while the remaining were rated of moderate (n= 36) or low/critically low (n= 35) quality.Conclusions: Results from the included reviews were mixed, with most reporting an inability to draw conclusions due to inconsistent findings and a lack of rigorous evidence. Mild harms were frequently reported, and it is possible the harms of cannabis-based medicines may outweigh benefits.Systematic review registration: The protocol for this scoping review was posted in the Open Access (https://ruor.uottawa.ca/handle/10393/37247).

12 April 2022 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
JNJeremy Y. Ng
Jeremy Y. Ng
TDTushar Dhawan
Tushar Dhawan
EDEkaterina Dogadova
Ekaterina Dogadova
ZTZhala Taghi-Zada
Zhala Taghi-Zada
AVAlexandra Vacca
Alexandra Vacca
DMDavid Moher
David Moher
Background: Identifying what therapies constitute complementary, alternative, and/or integrative medicine (CAIM) is complex for a multitude of reasons. An operational definition is dynamic, and changes based on both historical time period and geographical location whereby many jurisdictions may integrate or consider their traditional system(s) of medicine as conventional care. To date, only one operational definition of “complementary and alternative medicine” has been proposed, by Cochrane researchers in 2011. This definition is not only over a decade old but also did not use systematic methods to compile the therapies. Furthermore, it did not capture the concept “integrative medicine”, which is an increasingly popular aspect of the use of complementary therapies in practice. An updated operational definition reflective of CAIM is warranted given the rapidly increasing body of CAIM research literature published each year. Methods: Four peer-reviewed or otherwise quality-assessed information resource types were used to inform the development of the operational definition: peer-reviewed articles resulting from searches across seven academic databases (MEDLINE, EMBASE, AMED, PsycINFO, CINAHL, Scopus and Web of Science); the “aims and scope” webpages of peer-reviewed CAIM journals; CAIM entries found in online encyclopedias, and highly-ranked websites identified through searches of CAIM-related terms on HONcode. Screening of eligible resources, and data extraction of CAIM therapies across them, were each conducted independently and in duplicate. CAIM therapies across eligible sources were deduplicated. Results: A total of 101 eligible resources were identified: peer-reviewed articles (n = 19), journal “aims and scope” webpages (n = 22), encyclopedia entries (n = 11), and HONcode-searched websites (n = 49). Six hundred four unique CAIM terms were included in this operational definition. Conclusions: This updated operational definition is the first to be informed by systematic methods, and could support the harmonization of CAIM-related research through the provision of a standard of classification, as well as support improved collaboration between different research groups.

15 August 2012 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LWL Susan Wieland
L Susan Wieland
LFLouise Falzon
Louise Falzon
CSChris N Sciamanna
Chris N Sciamanna
KTKimberlee J Trudeau
Kimberlee J Trudeau
SBSuzanne Brodney
Suzanne Brodney
KDKarina W Davidson
Karina W Davidson

1 January 2018 in Nutrition
Verified
Journal Article
Closed access
EPElizabeth A Parker
Elizabeth A Parker
TRTina Roy
Tina Roy
CDChristopher R. D'ADamo
Christopher R. D'ADamo
LWL. Susan Wieland
L. Susan Wieland

1 June 2012 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
EMEric Manheimer
Eric Manheimer
SWSusan L Wieland
Susan L Wieland
KCKe Cheng
Ke Cheng
SLShih Min Li
Shih Min Li
XSXueyong Shen
Xueyong Shen
LLLixing Lao
Lixing Lao
A new systematic review and meta-analysis of randomized controlled trials (RCTs) to estimate the effects of acupuncture for treating IBS. METHODS: MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, Cumulative Index to Nursing and Allied Health, and the Chinese databases Sino-Med, CNKI, and VIP were searched through November 2011. Eligible RCTs compared acupuncture with sham acupuncture, other active treatments, or no (specific) treatment, and evaluated acupuncture as an adjuvant to another treatment. Our outcomes were overall IBS symptom severity and health-related quality of life. Dichotomous data were pooled to provide a relative risk (RR) of substantial improvement after treatment, and continuous data were pooled to provide a standardized mean difference (SMD) in post-treatment scores between groups. RESULTS: A total of 17 RCTs (N=1,806) were included. We found no evidence of an improvement with acupuncture relative to sham acupuncture on symptom severity (SMD=−0.11, 95% confidence interval (95% CI): −0.35 to 0.13; 4 RCTs) or quality of life (SMD=−0.03, 95% CI: −0.27 to 0.22; 3 RCTs). Because of the homogeneity of the results of the sham-controlled trials, results were unaffected by restriction to the four sham-controlled RCTs that used adequate randomization, blinding, and had few withdrawals/dropouts. Among RCTs that did not use a placebo control, acupuncture was more effective than pharmacological therapy (RR of symptom improvement=1.28, 95% CI: 1.12 to 1.45; 5 RCTs) and no (specific) treatment (RR = 2.11, 95% CI: 1.18 to 3.79; 2 RCTs). There was no difference between acupuncture andBifidobacterium(RR=1.07, 95% CI: 0.90 to 1.27; 2 RCTs) or between acupuncture and psychotherapy (RR=1.05, 95% CI: 0.87 to 1.26; 1 RCT). Acupuncture as an adjuvant to another Chinese medicine treatment was statistically significantly better than the other treatment alone, in trials with a high risk of bias (RR=1.17, 95% CI: 1.02 to 1.33; 4 RCTs). CONCLUSIONS: Sham-controlled RCTs have found no benefits of acupuncture relative to a credible sham acupuncture control on IBS symptom severity or IBS-related quality of life. In comparative effectiveness Chinese trials, patients reported greater benefits from acupuncture than from pharmacological therapies. Future trials may help clarify whether or not these reportedly greater benefits of acupuncture relative to pharmacological therapies are due entirely to patients' preferences for acupuncture or patients' greater expectations of improvement on acupuncture relative to drugs....